(READ) Review shows Merck’s newly-approved pill for Covid-19, only 30% effective

Below is an excerpt from Medpage Today. With the release of updated data, oral antiviral molnupiravir to treat high-risk COVID-19 showed only a 30% reduction in the risk of hospitalization and death, according to briefing documents from FDA staff. The agent’s sponsor, Merck, submitted data from the interim analysis of its phase III trial with […]

Share DeepPol